Patnaik MM - Search Results

1

Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms.

Shah MV, Mangaonkar AA, Begna KH, Alkhateeb HB, Greipp P, Nanaa A, Elliott MA, Hogan WJ, Litzow MR, McCullough K, Tefferi A, Gangat N, Patnaik MM, Al-Kali A, He R, Chen D. Shah MV, et al. Among authors: patnaik mm. Blood Cancer J. 2022 Jul 8;12(7):106. doi: 10.1038/s41408-022-00703-8. Blood Cancer J. 2022. PMID: 35803921 Free PMC article.

2

FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature.

Pardanani A, Ketterling RP, Li CY, Patnaik MM, Wolanskyj AP, Elliott MA, Camoriano JK, Butterfield JH, Dewald GW, Tefferi A. Pardanani A, et al. Among authors: patnaik mm. Leuk Res. 2006 Aug;30(8):965-70. doi: 10.1016/j.leukres.2005.11.011. Epub 2006 Jan 6. Leuk Res. 2006. PMID: 16406016

3

Eosinophilia: secondary, clonal and idiopathic.

Tefferi A, Patnaik MM, Pardanani A. Tefferi A, et al. Among authors: patnaik mm. Br J Haematol. 2006 Jun;133(5):468-92. doi: 10.1111/j.1365-2141.2006.06038.x. Br J Haematol. 2006. PMID: 16681635 Free article. Review.

4

Kit: molecule of interest for the diagnosis and treatment of mastocytosis and other neoplastic disorders.

Patnaik MM, Tefferi A, Pardanani A. Patnaik MM, et al. Curr Cancer Drug Targets. 2007 Aug;7(5):492-503. doi: 10.2174/156800907781386614. Curr Cancer Drug Targets. 2007. PMID: 17691909 Review.

5

The complete evaluation of erythrocytosis: congenital and acquired.

Patnaik MM, Tefferi A. Patnaik MM, et al. Leukemia. 2009 May;23(5):834-44. doi: 10.1038/leu.2009.54. Epub 2009 Mar 19. Leukemia. 2009. PMID: 19295544 Review.

6

Molecular diagnosis of myeloproliferative neoplasms.

Patnaik MM, Tefferi A. Patnaik MM, et al. Expert Rev Mol Diagn. 2009 Jul;9(5):481-92. doi: 10.1586/erm.09.29. Expert Rev Mol Diagn. 2009. PMID: 19580432 Review.

7

JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival.

Tefferi A, Lasho TL, Patnaik MM, Finke CM, Hussein K, Hogan WJ, Elliott MA, Litzow MR, Hanson CA, Pardanani A. Tefferi A, et al. Among authors: patnaik mm. Leukemia. 2010 Jan;24(1):105-9. doi: 10.1038/leu.2009.225. Epub 2009 Oct 22. Leukemia. 2010. PMID: 19847199

8

Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival.

Patnaik MM, Caramazza D, Gangat N, Hanson CA, Pardanani A, Tefferi A. Patnaik MM, et al. Eur J Haematol. 2010 Feb 1;84(2):105-8. doi: 10.1111/j.1600-0609.2009.01373.x. Epub 2009 Nov 6. Eur J Haematol. 2010. PMID: 19895568

9

Systemic fibrinolysis caused by tissue plasminogen activator-producing metastatic breast cancer.

Naina HV, Patnaik MM, Ali UA, Chen D, Ashrani AA. Naina HV, et al. Among authors: patnaik mm. J Clin Oncol. 2010 Apr 10;28(11):e167-8. doi: 10.1200/JCO.2009.25.2502. Epub 2010 Jan 11. J Clin Oncol. 2010. PMID: 20065179 No abstract available.

10

MPL mutation effect on JAK2 46/1 haplotype frequency in JAK2V617F-negative myeloproliferative neoplasms.

Patnaik MM, Lasho TL, Finke CM, Gangat N, Caramazza D, Siragusa S, Hanson CA, Pardanani A, Tefferi A. Patnaik MM, et al. Leukemia. 2010 Apr;24(4):859-60. doi: 10.1038/leu.2010.1. Epub 2010 Jan 28. Leukemia. 2010. PMID: 20111067 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

414 results

Search Page